Clinical Trial Update: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

View source ↗

Summary

A completed clinical trial evaluating whether Glatiramer Acetate (Copaxone) induces anti-inflammatory Type II monocytes in individuals with Multiple Sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

Sponsor: University of California, San Francisco | Conditions: Multiple Sclerosis | Status: COMPLETED